Loading data for HRTX — first visit, this takes a few seconds.

알림

Heron Therapeutics Inc. (HRTX)

NasdaqCM: HRTX · 실시간 가격 · USD

0.31

-0.01 (-3.13%)

종가 기준: Aug 26, 2026, 8:00 PM

0.31

+0.00%

애프터마켓: 4:01 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

-3.13% (1D)

데이터 없음

매수호가	0.27
시가총액	59.27M
매출 (ttm)	151.18M
순이익 (ttm)	-34.05M
	1.67
	-0.19
	n/a
	-2.84
P/B (ttm)	10.07
P/S (ttm)	0.39
실적 발표일	Nov 3, 2026

매도호가	0.36
거래량	2,882,690
평균 거래량 (20일)	3,543,882
시가	0.32
전일 종가	0.32
일중 범위	0.30 - 0.32
52주 범위	0.30 - 1.58
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

HRTX 소개

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release in...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Aug 26, 1987

직원 수 128

상장 거래소 NasdaqCM

티커 HRTX

웹사이트 https://www.herontx.com

전체 기업 정보

재무 실적

2025년 Heron Therapeutics의 매출은 154.9M로, 전년 144.28M 대비 7.36% 증가했습니다. 순이익은 -20.2M로, 48.71% 증가했습니다.

재무제표

어닝 서프라이즈

Heron Therapeutics가 Aug 10, 2026에 분기 실적을 발표했습니다:

매출 $34.71M 예상치 하회 $0, 및 -10.78% 전년 대비 감소.
EPS -0.03 예상치 하회 -0.01, 및 -50.00% 전년 대비 감소.

다음 실적 발표

Heron Therapeutics Inc.의 실적 발표 예정일은 Nov 3, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

2주 전 · GuruFocus.com

Heron Therapeutics Inc (HRTX) (Q2 2026) Earnings Call Highlights: Revenue Growth Amid Strategic ...

Company navigates mixed Q2 results with strong APONVIE growth, while withdrawing guidance due to CINVANTI patent challenges and exploring strategic alternatives.

2주 전 · InvestorsHub

Heron Therapeutics Withdraws 2026 Guidance as CINVANTI Patent Risk and Strategic Review Cloud Outlook

Heron Therapeutics reported modest second-quarter revenue growth, but uncertainty around potential generic CINVANTI competition and a strategic alternatives process prompted the company to withdraw it...

2주 전 · MarketBeat

Heron Therapeutics Q2 Earnings Call Highlights

Heron Therapeutics (NASDAQ:HRTX) reported second-quarter net revenue of $37.7 million, up from $34.7 million in the first quarter and $37.2 million in the comparable prior-year period, while managemen...

2주 전 · Zacks

Heron Therapeutics (HRTX) Reports Q2 Loss, Lags Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -50.00% and -11.17%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

2주 전 · Zacks

Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates

Verrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of +14.29% and +1.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock...

2 페이지 중 1

Heron Therapeutics Inc. (HRTX)